25 January 2018

Consilium Strategic Communications Sponsors Future of Healthcare Investor Forum

London, 25 January 2018, Consilium Strategic Communications, a global leader in strategic healthcare communications, today joins co-sponsors J.P. Morgan, Numis, Penningtons Manches, PwC and partners MedCity, the BioIndustry Association (BIA), and One Nucleus and London Stock Exchange to host the fourth Future of Healthcare Investor Forum at London Stock Exchange.

 

London, 25 January 2018, Consilium Strategic Communications, a global leader in strategic healthcare communications, today joins co-sponsors J.P. Morgan, Numis, Penningtons Manches, PwC and partners MedCity, the BioIndustry Association (BIA), and One Nucleus and London Stock Exchange to host the fourth Future of Healthcare Investor Forum at London Stock Exchange.

 

This one-day, invitation-only event will highlight the best innovation and explore current investment trends through a series of panels and keynote presentations from leading public and private UK and international life sciences companies. The Forum will tackle issues covering innovation in areas such as life sciences business models, respiratory therapies and for the first time, digital health.

 

 

“We are very pleased to be part of the Future of Healthcare Investor Forum and to see the data released today by London Stock Exchange and the BIA showing strength in the funding environment in the UK. The Forum provides investors with an opportunity to gain real insight into the sector, current investment trends, and leading technologies.”

Chris Gardner

Partner at Consilium Strategic Communications

In association with the Forum, London Stock Exchange has today revealed statistics which show the strength of the wider UK life sciences sector:

 

  • £2.4 billion raised in life sciences IPOs and further offerings on London Stock Exchange in 2017, up 20% compared to 2016
  • £2.1 billion raised in follow on capital a six-fold increase compared with 2016

 

The BIA and Informa Pharma Intelligence have also today released a new report which highlights in more detail the growing maturity of the UK biotech sector. It shows that UK biotech company IPOs raised more than twice as much money in 2017 than in 2016, and that the UK has the strongest clinical and preclinical pipeline in Europe.

 

Key statistics from Pipeline Progressing: the UK’s global bioscience cluster in 2017:

 

  • UK biotech company IPOs raised more than twice as much money in 2017 (£234m) than in 2016 (£105m)
  • UK biotech raised more on the public markets than in venture capital as UK companies matured and progressed through the funding lifecycle with £515m raised in venture capital, £234m raised in IPOs and £452m raised in follow on funding
  • The UK has the strongest pipeline in Europe across all preclinical and clinical stages, with 351 preclinical products, 43 phase I, 70 phase II and 15 phase III
  • LSE’s Main Market has seen major indirect investment through vehicles that fund the biopharma sector, including Arix Bioscience (£113m) and Biopharma Credit (£606m)
  • The 2017 IPO listings on Nasdaq (NuCana plc, Nightstar Therapeutics and Verona) show that the global demand for UK biotech companies is strong

 

The full Pipeline Progressing report can be accessed here:

http://bia.me/pipelineprogressing

 

Consilium Strategic Communications

 

Mary-Jane Elliott / Amber Fennell / Chris Gardner

Tel: +44(0)20 3709 5700

info@consilium-comms.com

www.consilium-comms.com

Follow us: @consiliumhc

 

About Consilium Strategic Communications

 

Consilium Strategic Communications is a global leader in strategic healthcare communications advisory with offices in Europe and across the US. Consilium's highly-skilled team provides strategic, long-term advice to healthcare companies, Boards, senior decision makers and executives on critical communications programmes and stakeholder challenges. The Company has established deep knowledge across all areas of the global healthcare sector through broad experience in representing international clients spanning the Fortune 500, FTSE100, FTSEurofirst 300 and FTSE250, through to discrete specialist reputation management projects.


Back to previous page